Kaituo Pharmaceutical-B (09939) rose 50% at the end of the session. As of press release, it had risen 45.83% to HK$1.75, with a turnover of HK$245 million, a record high.
The Zhitong Finance App learned that Kaituo Pharmaceutical-B (09939) rose 50% at the end of the session. As of press release, it had risen 45.83% to HK$1.75, with a turnover of HK$245 million. The turnover reached a record high.
According to the news, the phase IB/III clinical trial of KX-826 combined with minoxidil to treat androgenic alopecia (AGA) in Chinese adult males, developed independently by the company and potentially pioneered in its class, was recently approved by the State Drug Administration to evaluate the efficacy and safety of KX-826 and minoxidil in the treatment of adult male AGA patients in China. The company said it is carrying out and plans to launch multiple clinical trials of KX-826 to treat hair loss and acne, and continue to develop the use value of KX-826 in the dermatological field.